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ASPIRIN AND PLATELETS-A BRIEF REVIEW 
Introduction 
It has become increasingly apparent that inges-
tion of aspirin can bring about alteration of hemostatic 
parameters in normal sUbjects. Hypoprothrombinemia has 
been observed in patients 24-36 hr. after taking rela-
ti 1 1 d t d d f .. 1, 2 'th ve y arge an repea e oses 0 asp~r~n ,w~ 
complete reversal by administration of vitamin K. Gas-
trointestinal bleeding, unrelated to prothrombin levels, 
also occurs following aspirin ingestion. This has gen-
erally been attributed to a direct gastric mucosal irri-
tant effect 3 but is also seen following intravenous 
administration of aspirin4. Bone marrow depression with 
resultant thrombocytopenia has been reported5, 6 and is 
thought to be secondary to a systemic allergic mechanism. 
Within the last few years, one of the most intensively 
studied facets of aspirin is its effect on platelets and 
platelet aggregation. 
Platelet Function 
Platelets have two important properties, "ad-
hesiveness" and "aggregation." O'Brien7 defines adhes-
iveness as the property of platelets to adhere to a 
foreign substance and can be measured by passage of 
platelet-rich plasma through a glass bead columnS. 
Platelets will adhere to glass, collagen, and damaged 
cells but a difference in cation dependency suggests 
different mechanisms for platelet adhesion to glass as 
compared to organic particles. 
"Aggregation" of platelets is the property of 
platelets to clump together and is usually measured 
turbidometrically9. Platelet aggregation is calcium-
magnesium dependent and is induced by ADp
lO 
or an 
initiating factor. Initiating factors may be grouped 
t f · t . 11-13 into a composi e 0 SlX ca egorles : 
3 
(1) soluble enzymes such as thrombin and trypsin, 
(2) particulate matter such as collagen, 
(3) amines such as norepinephrine, 5-hydroxy-
tryptamine, and epinephrine, 
(4) saturated fatty acids, 
(5) triethyltin, 
(6) centrifugation. 
The aggregation produced by initiating factors 
when added in proper concentrations occurs in two phases: 
the first produced by the addition of the initiating factor 
(e.g., extrinsic ADP) and the second by further release 
14 
of ADP from the platelets • An increase in the amount 
of the initiating factor added to platelet-rich plasma 
14 
produces monophasic clumping by "abolishing the delayll 
in the release of ADP from the platelet. Thrombin will 
produce aggregation after a delay of 5-10 sec. presumably 
due to conversion of platelet ATP to ADP by thrombin. 
One hypothesis for ADP-induced platelet aggrega-
4 
tion is that conversion from nonsticky to sticky platelets 
is an energy requiring process supplied by breakdown of 
ATP to ADP15. Inhibition of aggregation by AMP and adeno-
sine would appear to act by product inhibition. 
ATPase 
ATP L <' ~======77 ADP 7 AMP 
~P04 + energy for aggregation 
Salzman et al. 16 , however, proposes that plate-
lets remain nonaggregated by an active energy-supplying 
mechanism which aids the platelet in preservation of its 
size and shape. The energy is supplied by breakdown of 
platelet ATP to ADP. 
ATPase 
ATP !:::/===?::7 ADP 
~P04 + energy for cellular maintenance 
When ADP is added to platelet suspension, the 
ATP is blocked by product inhibition, preventing energy 
production. The low energy state allows the platelet to 
swell, exposing receptor sites, and permits secondary 
bridging by fibrinogen (or another plasma protein) and 
calcium. Chambers et al17 has described an "ecto-ATPase,,18 
present on platelets which is inhibited by thrombasthenia 
5 
antisera and is calcium-magnesium dependent. This may be 
the needed ATPase to fit the theory of energy production. 
The Effect of Aspirin 
In 1966, Quick19 introduced the "aspirin toler-
ance test!! whereby the ingestion of 1.3 gm. of aspirin 
resulted in a small "but significant" increase in the 
bleeding time of more than one-half of his normal sub-
jects. This effect was not seen with 1.15 gm. of sodium 
salicylate. Quick attributed the increased bleeding 
times with aspirin to its acetyl linkage, suggesting 
that it was perhaps a competitive inhibitor of an enzyme 
in the platelet. 
Aspirin and Platelets 
Using a glass-bead method for determination of 
platelet stickiness, Morris
20 
noted a depression of plate-
let stickiness greater than 10% with 0.5 and 1.0 gm. in 
a dose-response fashion. The bleeding time was also pro-
longed. Using Born's method21 , Morris also showed that 
in vitro addition of salicylic acid produced an inhibition 
of ADP-induced aggregation. 
When platelet-rich plasma is drawn from subjects 
who have ingested aspirin, Weiss and Aledort 22 demonstrated 
significantly decreased platelet aggregation in the presence 
6 
of added connective tissue. This decreased aggregation 
was associated with an impaired ability to release in-
trinsic platelet ADP. Primary aggregation of platelet-
rich plasma by added ADP was not impaired. Zucker and 
Peterson23 have also demonstrated that the secondary 
aggregation phase (presumably secondary to release of 
endogenous ADP activity) produced by added ADP is abol-
ished 1-2 hr. following ingestion of 1.3 gm. of aspirin, 
but the primary aggregation phase is unaffected. 
24, 25 
O'Brien has been able to demonstrate 
that ingestion of as little as 0.15 gm. of aspirin will 
inhibit the secondary aggregation phase of adrenalin 
on platelet-rich plasma from these volunteers. This 
abnormality was found to persist for 2-5 days, in the 
absence of residual serum aspirin. However, incubation 
of I1normal" platelet-rich plasma with "aspirin ll plate-
let-rich plasma on subsequent days after aspirin inges-
tion resulted in a normal biphasic response to adrenalin, 
presumably by release of intrinsic ADP from the "normal ll 
platelets. Ingestion of sodium salicylate had no effect 
on secondary aggregation by adrenalin of the patient's 
platelet-rich plasma. This finding would suggest that 
the short-lived aspirin molecule may permanently damage 
a single enzyme system of the platelet
12 • MacMillan26 
also feels that the action of aspirin is "inside" the 
platelet because primary phase aggregation by the addition 
7 
of extrinsic ADP is not affected. 
Because aspirin inhibits the second wave of 
aggregation induced by added ADP, adrenalin, collagen, 
triethyltin, and centrifugation, O'Brien has inferred 
that the basic mechanism is inhibition of release of 
intrinsic ADP. Because aspirin blocks the self-stimu-
lating cyclic release of ADP, both O'Brien and MacMillan 




has also shown that other anti-in-
flammatory agents can inhibit secondary aggregation of 
platelet-rich plasma by adrenalin. He proposed two 
alternate theories for these findings: (1) that these 
drugs inhibit inflammatory changes and the platelet 
response by the same mechanism; or (2) that their anti-
inflammatory activity is mediated (at least in part) by 
the effect on platelets. 
The effect of aspirin on platelet aggreation 
has many implications. QuiCk19 has shown that aspirin 
ingestion can be used as a diagnostic aid in evaluation 
of patients with clinical Minot-Von Willebrand syndrome. 
In addition, he suggests that his "aspirin tolerance test" 
may be used to detect the syndrome in patients with a 
characteristic history of bleeding and a typical heredi-
tary pattern, but with a normal bleeding time. Such pro-
longations of the bleeding time suggests that a platelet 
function is impaired. 
Thrombasthenin is postulated as a surface 
enzyme leading to contractility that is absent in one 
type of thrombasthenia and considered by Chambers
17 
to 
be identical with "ecto-ATPase." After preparing anti-
body to thrombasthenin he demonstrated inhibition of 
ecto-ATPase, but no investigation has been made of 
enhanced inhibition by aspirin. 
The production of hemorrhagic diatheses by 
8 
aspirin in normal patients should also be considered. 
The Portsmouth syndrome as defined by O'Brien28 consists 
of (1) a history of bleeding, (2) a moderately prolonged 
bleeding time, (3) increased adhesiveness of platelets 
during passage through a glass bead column, (4) normal 
plasma AHG levels, and (5) decreased aggregation of 
platelets in the presence of collagen. 29 Evans suggested 
that this syndrome could be due to the administration of 
aspirin, yet the majority of patients had no history of 
recent aspirin ingestion and, in addition, aspirin is 
not known to affect platelet survival during passage 
through a glass bead cOlumn30 • 
Nicolaides 3l also reported spontaneous bruising 
in patients with a history of aspirin ingestion, the 
phenomenon subsiding after cessation of aspirin. Our 
32 
own studies suggest an individual susceptibility to 
prolongation of the bleeding time by aspirin, as only 
38% of the "normal!! volunteers showed an increase in 
bleeding time two hours' post-aspirin ingestion. It 
is suggested that this difference in response repre-
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INTRODUCTION 
It has become increasingly apparent that ingestion of aspirin can bring 
about alteration of hemostatic parameters in normal subjects. Hypoprothrom-
binemia has been observed in patients 24-36 hr after taking relatively large 
and repeated doses of aspirin [1,2], with complete reversal by administra-
tion of vitamin K. Gastrointestinal bleeding, unrelated to prothrombin levels, 
also occurs following aspirin ingestion. This has generally been attributed 
to a direct gastric mucosal irritant effect [3] but is also seen following in-
travenous administration of aspirin [4]. Bone marrow depression with re-
sultant thrombocytopenia has been reported [5,6] and is thought to be second-
ary to a systemic allergic mechanism. Within the last few years, one of the 
most intensively studied facets of aspirin is its effect on platelets and plate-
let aggregation. 
PLATELET FUNCTION 
Platelets have two important properties, "adhesiveness" and "aggrega-
tion." OtBrien [7 ] defines adhesiveness as the property of platelets to ad-
here to a foreign substance and can be measured by passage of platelet-rich 
plasma through a glass bead column [8]. Platelets will adhere to glass, 
collagen, and damaged cells but a difference in cation dependency suggests 
different mechanisms for platelet adhesion to glass as compared to organic 
particles. 
"Aggregation" of platelets is the property of platelets to clump together 
and is usually measured turbidometrically [9]. Platelet aggregation is cal-
cium- magnesium dependent and is induced by ADP [10] or an initiating 
factor. Initiating factors may be grouped into a composite of six categories 
[11-13] : 
*Supported by Poison Control Fellowship, Division of Maternal and Child Health, De-
partment of Health, State of Nebraska at Childrens Memorial Hospital, Omaha, Nebraska. 
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(1) soluble enzymes such as thrombin and trypsin, 
(2) particulate matter such as collagen, 
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(3) amines such as norephinephrine, 5-hydroxytryptamine, and 
epinephrine, 
(4) saturated fatty acids, 
(5) triethyltin, 
(6) centrifugation. 
The aggregation produced by initiating factors when added in proper concen-
trations Occurs in two phases: the first produced by the addition of the initiat-
ing factor (e.g., extrinsic ADP) and the second by further release of ADP from 
the platelets [14]. An increase in the amount of the initiating factor added to 
platelet-rich plasma produces monophasic clumping by "abolishing the delay" 
[14] in the release of ADP from the platelet. Thrombin will produce aggrega-
tion after a delay of 5-10 sec presumably due to conversion of platelet ATP 
to ADP by thrombin. 
One hypothesis for ADP-induced platelet aggregation is that conversion 
from nonsticky to sticky platelets is ~n energy requiring process supplied by 
breakdown of ATP to ADP [15J. Inhioition of aggregation by AMP and adenos-
ine would appear to act by product inhibition. 
ATP 1TPase ADP /' AMP 
~P04 + en:rgy for aggregation 
Salzman et al. [16 J, however, propose that platelets remain nonaggregat-
ed by an active energy-supplying mechanism which aids the platelet in preser-
vation of its size and shape. The energy is supplied by breakdown of platelet 
ATP to ADP. 
ATP 1TPase ADP 
;;:: 
~P04 + energy for cellular maintenance 
When ADP is added to platelet suspension, the ATP is blocked by product in-
hibition, preventing energy production. The low energy state allows the 
platelet to swell, exposing receptor sites, and permits secondary bridging by 
fibrinogen (or another plasma protein) and calcium. Chambers et al. [17] has 
described an "ecto-ATPase" [18] present on platelets which is inhibited by 
thrombasthenia antisera and is calcium-magnesium dependent. This may be 
the needed ATPase to fit the theory of energy production. 
THE EFFECT OF ASPIRIN 
In 1966, Quick [19] introduced the "aspirin tolerance test" whereby the 
ingestion of 1. 3 gm of aspirin resulted in a small "but significant" increase 
in the bleeding time of more than one-half of his normal subjects. This ef-
fect was not seen with 1.15 gm of sodium salicylate. Quick attributed the in-
creased bleeding times with aspirin to its acetyl linkage, suggesting that it 
was perhaps a competitive inhibitor of an enzyme in the platelet. 
-----------~--"-----.,-....... -------------------------
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Using a glass-bead method for determination of platelet stickiness, 
Morris [20] noted a depression of platelet stickiness greater than 10% with 
0.5 and 1.0 gm in a dose-response fashion. The bleeding time was also pro-
longed. Using Born's method [21], Morris also showed that in vitro addi-
tion of salicylic acid produced an inhibition of ADP- induced aggregation. 
When platelet-rich plasma is drawn from subjects who have ingested 
aspirin, Weiss and Aledort [22] demonstrated significantly decreased plate-
let aggregation in the presence of added connective tissue. This de-
creased aggregation was associated with an impaired ability to release in-
trinsic platelet ADP. Primary aggregation of platelet-rich plasma by added 
ADP was not impaired. Zucker and Peterson [23] have also demonstrated 
that the secondary aggregation phase (presumably secondary to release of 
endogenous ADP activity) produced by added ADP is abolished 1- 2 hr follow-
ing ingestion of 1.3 gm of aspirin, but the primary aggregation phase is unaf-
fected. 
0' Brien [24,25] has been abl e to demonstrate that ingestion of as littl e 
as 0.15 gm of aspirin will inhibit the secondary aggregation phase of adrenalin 
on platelet-rich plasma from these volunteers. This abnormality was found 
to persist for 2-5 days, in the absence of residual serum aspirin. However, 
incubation of "normal" platelet-rich plasma 'with "aspirin" platelet-rich 
plasma on subsequent days after aspirin ingestion resulted in a normal bi-
phasic response to adrenalin, presumably by release of intrinsic ADP from 
the "normal" platelets. Ingestion of sodium salicylate had no effect on second-
ary aggregation by adrenalin of the patient's platelet-rich plasma. This finding 
would suggest that the short-lived aspirin molecule may permanently damage 
a single enzyme system of the platelet [12]. MacMillan [26] also feels that 
the action of aspirin is "inside" the platelet because primary phase aggrega-
tion by the addition of extrinsic ADP is not affected. 
Because aspirin inhibits the second wave of aggregation induced by 
added ADP, adrenalin, collagen, triethyltin, and centrifugation, 0' Brien has 
inferred that the basic mechanism is inhibition of release of intrinsic ADP. 
Because aspirin blocks the self-stimulating cyclic release of ADP, both 
O'Brien and MacMillan have suggested aspirin might be ideal as an anti-
thrombotic agent. 
O'Brien [27] has also shown that other anti-inflammatory agents can 
inhibit secondary aggregation of platelet-rich plasma by adrenalin. He pro-
posed two alternate theories for these findings: (1) that these drugs inhibit 
inflammatory changes and the platelet response by the same mechanism; or 
(2) that their anti-inflammatory activity is mediated (at least in part) by the 
effect on platelets. 
The eff ect of aspirin on platelet aggregation has many implications. 
Quick [19] has shown that aspirin ingestion 'can be used as a diagnostic aid 
in evaluation of patients with clinical Minot- Von Willebrand syndrome. In 
addition, he suggests that his "aspirin tolerance test" may be used to detect 
the syndrome in patients with a characteristic history of bleeding and a typi-
cal hereditary pattern, but with a normal bleeding time. Such prolongations 
of the bleeding time suggest that a platelet function is impaired. 
Thrombasthenin is postulated as a surface enzyme leading to contract-
ility that is absent in one type of thrombasthenia and considered by Chambers 
[17] to be identical with !lecto-ATPase." After preparing antibody to throm-
basthenin he demonstrated inhibition of ecto-ATPase, but no investigation has 
been made of enhanced inhibition by aspirin. 
,,-, 
,-
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The production of hemorrhagic diatheses by aspirin in normal patients 
should also be considered. The Portsmouth syndrome as defined by O'Brien 
[ 28] consists of (1) a history of bleeding, (2) a moderately prolonged bleed-
ing time, (3) increased adhesiveness of platelets during passage through a 
glass bead column, (4) normal plasma AHG levels, and (5) decreased aggrega-
tion of platelets in the presence of collagen. Evans [29] suggested that this 
syndrome could be due to the administration of aspirin, yet the majority of 
patients had no history of recent aspirin ingestion and, in addition, aspirin 
is not known to affect platelet survival during passage through a glass bead 
column [30 J . 
Nicolaides [31] also reported spontaneous bruising in patients with a 
history of aspirin ingestion, the phenomenon subsiding after cessation of as-
pirin. Our own studies [32] suggest an individual susceptibility to prolonga-
tion of the bleeding time by aspirin, as only 38% of the "normal" volunteers 
showed an increase in bleeding time two hours post- aspirin ingestion. It is 
suggested that this difference in response represents a common genetic 
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